3, 4 It has been projected that this disease will affect 33.5% of the adult population by 2030, of which 27% will suffer from NASH. 2 Although the real prevalence of NAFLD may vary depending on the sensitivity of the detection method used, there has been a marked elevation in the prevalence of NAFLD in recent years. 1 NAFLD encompasses a wide range of liver disorders including simple hepatic steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and eventually hepatocellular carcinoma, with a complex ‘multi-hit’ pathophysiology. Non-alcoholic fatty liver disease (NAFLD), caused by accumulation of triglyceride (TG) in the cytoplasm of hepatocytes, is regarded as one of the most common liver pathologies worldwide. No significant differences were found between the two study groups in terms of other hematological parameters.Ĭonclusion: The results of the current study indicated that OEA supplementation had beneficial effects on LDL-C/HDL-C, TG/HDL-C, and non-HDL-C/HDL-C ratios as well as RDW in obese patients with NAFLD. Additionally, OEA supplementation could significantly decrease the levels of red blood cell distribution width (RDW) compared to the placebo at the endpoint after considering potential confounding variables (95% CI: -0.56 to -0.003, P = 0.041). Results : After adjustment for potential confounding factors, between group analyses demonstrated a significantly lower LDL-C/HDL-C, TG/HDL-C, and non-HDL-C/HDL-C ratios in the OEA group compared to the placebo, post-intervention (95% confidence interval :0.06 to 0.85, P = 0.024 95% CI: -2.06 to -0.05, P = 0.039 95% CI: -1.05 to -0.02, P = 0.042,respectively).
Atherogenic factors including total cholesterol/high-density lipoprotein cholesterol (HDL-C),low-density lipoprotein cholesterol (LDL-C)/HDL-C, triglyceride (TG)/HDL-C, non-HDL-C/HDL-C ratios and non-HDL-C level, as well as hematological parameters were assessed before and after intervention.
#Tg pro 2.61 plus
Methods: In this triple-blinded, randomized, placebo-controlled clinical trial, 76 obese patients with NAFLD confirmed by ultra-sonographic findings were randomly assigned to receive a weight reduction diet plus either 250 mg OEA (n=38) or placebo (n=38) for 12 weeks.
#Tg pro 2.61 trial
The current interventional trial aimed to evaluate the effects of supplementation with oleoylethanolamide (OEA) in combination with weight loss intervention on some atherogenic indices as well as hematological parameters in patients newly diagnosed with NAFLD. Background: Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in the world.
0 kommentar(er)
